Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 14
2004 12
2005 8
2006 11
2007 7
2008 9
2009 13
2010 12
2011 11
2012 19
2013 34
2014 47
2015 65
2016 36
2017 32
2018 23
2019 37
2020 22
Text availability
Article attribute
Article type
Publication date

Search Results

372 results
Results by year
Filters applied: . Clear all
Page 1
The evolving role of microsatellite instability in colorectal cancer: A review.
Gelsomino F, Barbolini M, Spallanzani A, Pugliese G, Cascinu S. Gelsomino F, et al. Among authors: Cascinu S. Cancer Treat Rev. 2016 Dec;51:19-26. doi: 10.1016/j.ctrv.2016.10.005. Epub 2016 Oct 27. Cancer Treat Rev. 2016. PMID: 27838401 Review.
Addressing the challenges of pancreatic cancer: future directions for improving outcomes.
Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Hidalgo M, et al. Among authors: Cascinu S. Pancreatology. 2015 Jan-Feb;15(1):8-18. doi: 10.1016/j.pan.2014.10.001. Epub 2014 Oct 17. Pancreatology. 2015. PMID: 25547205 Free article. Review.
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. Piva F, et al. Among authors: Cascinu S. Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Peeters M. Price T, et al. Among authors: Cascinu S. Eur J Cancer. 2016 Nov;68:51-59. doi: 10.1016/j.ejca.2016.08.010. Epub 2016 Oct 5. Eur J Cancer. 2016. PMID: 27716478 Free article. Clinical Trial.
Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain.
Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M; Early Strong Opioid Treatment Study (ESOT) Investigators. Bandieri E, et al. Among authors: Cascinu S. J Clin Oncol. 2016 Feb 10;34(5):436-42. doi: 10.1200/JCO.2015.61.0733. Epub 2015 Dec 7. J Clin Oncol. 2016. PMID: 26644526 Clinical Trial.
Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S. Spallanzani A, et al. Among authors: Cascinu S. Expert Rev Anticancer Ther. 2018 Nov;18(11):1069-1076. doi: 10.1080/14737140.2018.1524297. Epub 2018 Sep 21. Expert Rev Anticancer Ther. 2018. PMID: 30220234 Review.
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis.
Toss A, Venturelli M, Sperduti I, Molinaro E, Isca C, Barbieri E, Piacentini F, Omarini C, Cortesi L, Cascinu S, Moscetti L. Toss A, et al. Among authors: Cascinu S. Clin Breast Cancer. 2019 Dec;19(6):e701-e716. doi: 10.1016/j.clbc.2019.06.011. Epub 2019 Jul 24. Clin Breast Cancer. 2019. PMID: 31427171 Review.
Gastric cancer: Translating novels concepts into clinical practice.
Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S. Salati M, et al. Among authors: Cascinu S. Cancer Treat Rev. 2019 Sep;79:101889. doi: 10.1016/j.ctrv.2019.101889. Epub 2019 Aug 14. Cancer Treat Rev. 2019. PMID: 31445415 Review.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
[Gastric carcinoma: an evolutionary scenario.].
Gelsomino F, Spallanzani A, De Vita F, Di Bartolomeo M, Gavazzi C, Rimassa L, Cascinu S. Gelsomino F, et al. Among authors: Cascinu S. Recenti Prog Med. 2017 Mar;108(3):120-127. doi: 10.1701/2656.27234. Recenti Prog Med. 2017. PMID: 28398405 Review. Italian.
372 results
Jump to page
Feedback